Abstract
Cancer and its treatment are recognized risk factors for VTE. Compliance rate with published VTE prophylaxis guidelines is low. Decision on when to offer prophylaxis for hospitalized cancer patients is difficult to make. This paper describes current clinical practice in offering VTE prophylaxis to hospitalized cancer patients. Prophylaxis rate and rate of VTE will be correlated with the risk level. We prospectively followed all consecutive adult cancer patients admitted to medical units over a 5-month period. Caprini risk assessment model, with some modifications, was utilized to determine risk of VTE. Six hundred and six patients (51% males, median age 52 years, range 18–91) were included. Reasons for admission included infections (25%), chemotherapy (22%) and palliative care (10%). In addition to cancer, the most frequently encountered risk factors for VTE were: Immobilization (35%), age > 60 years (31%) and body mass index > 30 in (20%). Patients were grouped according to their total risk score: low (9%), moderate (44%) and high risk (47%). VTE prophylaxis rate was 55.1% for the whole study group. Following discharge, patients were followed for 60 days. The incidence of VTE was 3.4% in the moderate and 4.2% in the high risk groups, while none in the low risk group developed VTE. Many additional risk factors for VTE are usually encountered in hospitalized cancer patients. Cancer alone may not be an enough reason for VTE prophylaxis. Risk assessment model able to stratify patients into different risk categories will simplify decision making and enhance VTE prophylaxis rate.


Similar content being viewed by others
References
Kniffin WD, Baron JA, Barret J, Bikmeyer JD, Anderson FA (1994) The epidemiology of pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861–866
Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26:115–117
Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815
Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245–1248
Thodiyil PA, Kakkar AK (2002) Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87:1076–1077
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7
Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE et al (1992) The clinical course of pulmonary embolism. N Engl J Med 326:1240–1245
Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264
Sørensen HT, Mellemkj’r L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850
Caprini J, Arcelus J, Reyna J (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38:12–19
Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, Glezer S, Thabane L, Sebaldt RJ, CURVE Study Investigators (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119:145–155
Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr, ENDORSE Investigators (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394
Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, IMPROVE Investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 132:936–945
Ageno W, Squizzato A, Ambrosini F et al (2002) Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87:746–750
Chopard P, Dorffler-Melly J, Hess U et al (2005) Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 257:352–357
Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suarez C, Otero R, RIETE Investigators (2004) The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2:1889–1891
Motykie G, Zebala L, Caprini J, Lee C, Arcelus J, Reyna J, Cohen E, Courtney T, Sullivan L (2000) A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis 9:253–262
Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575–579
Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464
Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89:640–646
Gerber DE, Grossman SA, Streiff MB (2006) Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24:1310–1318
Andtbacka RH, Babiera G, Singletary SE et al (2006) Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243:96–101
Chew HK, Wun T, Harvey DJ et al (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25:70–76
Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and risk of venous thrombosis. JAMA 293:715–722
Haddad TF, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:547–666
Geerts W, Bergqvist D, Pineo G et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:381–453
American Society of Clinical Oncology Guideline (2007) Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505
NCCN, clinical practice guidelines in oncology (2008) Venous thromboembolic disease. J Natl Compr Canc Netw 6:716–753
Hull RD, Schellong SM, Tapson VF et al (2006) Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 22:31–38
Bosson JL, Pouchain D, Bergmann JF, for the ETAPE Study Group (2006) A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices. J Intern Med 260:168–176
Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907
Ay C, Simanek R, Vormittag R et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112:2703–2708
Acknowledgment
The authors would like to thank Dr. L. Zaru and Dr. J. Caprini, for their valuable comments in preparing this manuscript and Mr. A. Harb for his help in preparing the illustrations.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abdel-Razeq, H.N., Hijjawi, S.B., Jallad, S.G. et al. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. J Thromb Thrombolysis 30, 286–293 (2010). https://doi.org/10.1007/s11239-010-0445-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-010-0445-9